Vaccines against varicella zoster virus gene 63 product
AssigneeSmithKline Beecham Biologicals s.a.
InventorsBernard Rentier, Catherine Sadzot
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions for the treatment or prevention of Zoster of individuals infected with Varicella Zoster virus (VZV), and to the prevention and treatment of Varicella infections. The compositions of the invention comprise the protein encoded by VZV gene 63 or an immunologically active derivative thereof. The invention further relates to compositions containing DNA or RNA corresponding to VZV gene 63.
Claims12
A pharmaceutical composition comprising Varicella Zoster Virus IE63 protein or an immunologically functional derivative and a pharmaceutically acceptable excipient.
A pharmaceutical composition comprising a nucleic acid encoding IE63 or an immunologically functional derivative thereof.
IE63 gene protein or immunologically functional derivative thereof for use in medicine.
Use of IE63 protein or an immunologically active derivative thereof for the manufacture of a medicament for the prevention or amelioration of Varicella or Zoster.
A pharmaceutical composition as claimed in claim 9 wherein the antigen is presented as an oil in water emulsion together with QS21 and 3D-MPL.
A method of producing a pharmaceutical composition comprising a Varicella Zoster virus IE63 protein, nucleic acid or immunologically functional derivative thereof, comprising mixing said protein, nucleic acid or derivative with a pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.